09:23 AM EDT, 10/06/2025 (MT Newswires) -- Gilead Sciences ( GILD ) said in a regulatory filing Monday that it has settled lawsuits with Lupin, Cipla, and Laurus Labs, which filed abbreviated new drug applications with the US Food and Drug Administration to market generic versions of HIV treatment Biktarvy.

The settlements stipulate that no generic versions are expected before April 1, 2036, in the US for Biktarvy tablets containing 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide, according to the filing with the US Securities and Exchange Commission.

Shares of Gilead Sciences ( GILD ) rose more than 4% in recent premarket activity Monday.